United States Biomarkers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states biomarkers market size is expected to grow from USD 20.19 billion in 2025 to USD 21.75 billion in 2026 and is forecast to reach USD 31.58 billion by 2031 at 7.74% CAGR over 2026-2031. This report is Segmented by Product (Consumables, Instruments, and Services & Software), Disease (Oncology, Cardiovascular Disorders, and More), Type (Efficacy Biomarkers, Safety Biomarkers, and Validation Biomarkers), Mechanism (Genetic Biomarkers, and More), and Application (Clinical Diagnostics, Drug Discovery & Development, and More). The Market Forecasts are Provided in Terms of Value (USD).

United States Biomarkers Market Trends and Insights

Rising Oncology Burden and Chronic Disease Prevalence in the U.S.

Cancer incidence projections indicate that the United States will see around 2 million new diagnoses annually through 2030, with lung and colorectal cancers representing large case volumes that benefit from biomarker-guided therapy selection. Chronic cardiovascular and metabolic conditions affect a large adult population, which sustains demand for cardiac and metabolic biomarkers embedded in treatment protocols across health systems. An aging demographic profile, with adults aged 65 and older expected to represent a rising share of the U.S. population by 2030, is increasing co-morbidities and encouraging multi-disease panels that streamline workflows for faster treatment initiation. Molecular profiling identifies actionable mutations in a significant share of advanced-stage cancers, which enables enrollment in precision trials and access to targeted therapies that outperform empirical regimens in specific settings. Regulatory programs such as the FDA’s tumor-agnostic biomarker policies and laboratory quality rules under CLIA continue to standardize assay performance, which supports payer confidence in the United States biomarkers market.

CMS Coverage Pilots for Blood-Based Neurodegenerative Biomarkers Catalyzing Earlier Detection

CMS draft coverage determinations in 2024 for plasma assays that measure phosphorylated tau and amyloid-beta ratios recognized their role in ruling out Alzheimer pathology in patients with mild cognitive impairment. Coverage with evidence development models require prospective registries to gather outcomes, which link reimbursement to real-world performance and clinical benefit. Clinicians are layering blood tests into diagnostic workflows, which shortens time to diagnosis and supports care planning earlier in the disease course. Private insurers are observing Medicare pilots and adapting policies that use biomarker documentation as a predicate for specialty referrals in older adults. Diagnostic companies are scaling immunoassay and mass spectrometry platforms for high-volume processing as coverage expands beyond specialty centers. CLIA and local or national coverage determinations continue to anchor quality and access parameters for decentralized testing sites in the United States biomarkers market.

Complex Reimbursement and Evolving FDA IVD/LDT Regulation Increases Time-to-Market

The FDA’s proposed framework to regulate laboratory-developed tests expands premarket review expectations for in-house assays, which lengthens development cycles and increases submission costs for hospital and academic laboratories. Many institutions are reassessing innovation pipelines or seeking commercial partners that can shoulder regulatory and quality requirements under the United States biomarkers market. Fragmented coverage policies across Medicare Administrative Contractors create region-by-region variability in approvals that constrains predictable reimbursement. Prior authorization and medical necessity checks add administrative steps that lower ordering rates even for tests with strong clinical evidence. The absence of specific CPT codes for newer biomarker categories often forces use of miscellaneous codes that pay at lower rates or face denials, which delays adoption. These barriers collectively slow market entry and scale for novel assays that would otherwise meet clinical needs.

Other drivers and restraints analyzed in the detailed report include:

• Data Liquidity via TEFCA/USCDI+ Enabling RWE Pipelines for Validation and Label Expansion
• Falling NGS/Multi-Omics Costs Enabling Broader Discovery and Clinical Validation
• High Assay Development and Multi-Site Clinical Validation Costs

Segment Analysis

Oncology accounted for 36.02% of disease-specific revenue in 2025 supported by widespread adoption of comprehensive genomic profiling for tumor characterization and therapy selection. The United States biomarkers market has embedded testing for targets that guide treatment in non-small cell lung cancer, colorectal cancer, breast cancer, and melanoma, and this underpins clinical trial enrollment and access to targeted agents. Neurological Disorders are expected to grow at a 8.86% CAGR through 2031 as plasma phospho-tau and amyloid assays move into routine use in primary care to triage suspected Alzheimer cases after recent coverage pilots. Cardiovascular biomarkers such as high-sensitivity troponin and natriuretic peptides support guideline-driven care that uses serial measurements to titrate therapy and assess residual risk in outpatient management. Immunology programs rely on biomarkers such as C-reactive protein and anti-CCP antibodies, though expansion is tempered by market maturity and fewer novel markers with superior performance.

Renal and urologic testing for chronic kidney disease staging remains essential, although pricing pressure challenges revenue growth as payers apply value-based models. Infectious disease and sepsis biomarkers continue to support stewardship protocols that target early intervention and better antibiotic use in hospital settings. Metabolic and endocrine biomarkers like hemoglobin A1c and TSH sustain volume through population health initiatives that identify and monitor at-risk individuals. Emerging areas in respiratory and gastrointestinal disorders include noninvasive fibrosis staging and phenotype-based asthma assessment, which may reduce reliance on invasive procedures once validation completes. The United States biomarkers market continues to see oncology as the anchor for precision diagnostics while neurology is the fastest-moving disease area based on recent coverage trends and new blood-based modalities.

Consumables held 51.78% of revenue in 2025 as labs across hospitals, reference centers, and pharma research maintained high-volume ordering for reagents and kits across immunoassays, PCR, and sequencing workflows. The United States biomarkers market continues to depend on stable supply chains for these core inputs, which underpins routine testing across oncology, cardiology, and infectious disease programs. Services & Software is the fastest-growing category at a 10.05% CAGR through 2031, driven by cloud bioinformatics that automates variant calling, annotation, and report generation aligned to clinical standards for structured results. Health systems are embedding AI-enabled interpretation modules within EHRs to route clinically actionable findings into care pathways that improve ordering consistency and turnaround times. Vendors are differentiating with pharmacogenomic decision support and longitudinal tracking of circulating tumor DNA changes, which help clinicians adapt therapy sequences. The United States biomarkers industry is also seeing bundled offerings that combine wet-lab processing with expert review, which simplifies staffing needs for community providers.

Instrument demand remains mixed as cost containment pressures influence capital budgets, yet upgrades to higher-throughput sequencers and automation platforms continue where scale brings operating margin benefits. Reference labs are outsourcing specialist interpretation to centralized teams that run molecular tumor boards and hereditary risk consultations, which can improve clarity and reduce variability in recommendations. Software components that output patient-specific results fall within CLIA oversight, which requires validation that automation yields concordant results compared to expert review. The United States biomarkers market benefits from investments in template-based reporting and standardized codes that reduce manual mapping across LOINC and SNOMED terminologies. These product-layer dynamics reinforce a shift toward recurring revenue streams from analytics and services that complement consumable volumes.

Complete Report Scope:

• By Disease
  • Oncology
  • Cardiovascular Disorders
  • Neurological Disorders
  • Immunological & Inflammatory Disorders
  • Renal & Urologic Disorders
  • Infectious Diseases & Sepsis
  • Metabolic & Endocrine Disorders
  • Respiratory Disorders
  • Gastrointestinal & Hepatic Disorders
• By Type
  • Efficacy Biomarkers
    • Prognostic Biomarkers
    • Predictive Biomarkers
    • Pharmacodynamic Biomarkers
    • Surrogate Endpoint Markers
  • Safety Biomarkers
  • Validation Biomarkers
• By Mechanism
  • Genetic (Genomic) Biomarkers
  • Epigenetic Biomarkers
  • Proteomic Biomarkers
  • Metabolomic Biomarkers
  • Lipidomic Biomarkers
  • Imaging Biomarkers
• By Application
  • Clinical Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Disease Risk Assessment
  • Prognosis & Monitoring
• By Product
  • Consumables
  • Instruments
  • Services & Software

List of Companies Covered in this Report:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd (Roche Diagnostics)
• Thermo Fisher Scientific
• QIAGEN
• Danaher Corporation (Beckman Coulter Diagnostics)
• Siemens Healthineers
• Bio-Rad Laboratories
• Agilent Technologies
• Illumina
• Revvity, Inc. (formerly PerkinElmer Life Sciences)
• Merck KGaA (MilliporeSigma in the U.S.)
• Beckton Dickinson
• Hologic
• Sysmex Corporation (Sysmex Inostics)
• Myriad Genetics
• Quanterix Corporation
• GE HealthCare Technologies Inc.
• bioMérieux S.A.
• Exact Sciences
• Guardant Health, Inc.
• Natera, Inc.
• GRAIL, LLC
• Foundation Medicine, Inc.
• Veracyte, Inc.
• Bio-Techne
• Olink Holding AB (publ)
• Seer, Inc.
• Standard BioTools Inc. (including SomaLogic)
• Adaptive Biotechnologies Corp.
• Tempus Labs, Inc.
• Eurofins
• 10x Genomics, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support